NCT01609790 2022-07-21
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
5 trialsNCT01664182 2022-06-07
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01553188 2019-03-05
AMG 386 and Abiraterone for Advanced Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01210222 2018-02-23
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT01623869 2015-10-19
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed